Company Profile
Insmed Stock Price, News & Catalysts
- Ticker:
- INSM
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
108.76 USD (-1.13%)
Close
Last updated: November 5, 2026
22.5B USD
Market cap
Why the stock is moving
Following the latest company update, āInsmed to Present at November and December 2026 Investor Conferencesā, INSM closed up 5.32% at $110.00 on Nov 4, 2026. The move occurred in the trading session associated with this company update.
Company overview
Serious and Rare Diseases
Insmed develops and commercializes therapies for serious pulmonary and rare diseases. Its portfolio combines marketed respiratory medicines with late-stage inhaled therapies and earlier gene-therapy programs.
Commercial Respiratory Portfolio
BRINSUPRI, or brensocatib, is a DPP1 inhibitor for non-cystic-fibrosis bronchiectasis. ARIKAYCE is an inhaled liposomal amikacin therapy for *Mycobacterium avium* complex lung disease.
TPIP
Treprostinil palmitil inhalation powder is a long-acting inhaled prostanoid in Phase 3 development for pulmonary arterial hypertension, with additional programs planned in progressive and idiopathic pulmonary fibrosis.
Earlier Pipeline
INS1033 is a second DPP1 inhibitor approaching the clinic, while INS1203 is a gene-therapy candidate for Stargardt disease.
Future catalysts
- Submission of Phase 3 ENCORE data to Japan's PMDA in the fourth quarter of 2026 to support an expanded ARIKAYCE label.
- Initiation of a Phase 3 TPIP study in idiopathic pulmonary fibrosis in the first half of 2027.
- Completion of enrollment in the Phase 3 PALM-ILD study in the first half of 2028.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Insmed (INSM)?
Insmed (INSM) most recently closed at 108.76 USD, a -1.13% move versus the previous session.
What is the market cap of Insmed (INSM)?
Insmed currently has a market capitalization of 22.5B USD on BioPharmSignal.
What does Insmed do?
Serious and Rare Diseases Insmed develops and commercializes therapies for serious pulmonary and rare diseases. Its portfolio combines marketed respiratory medicines with late-stage inhaled therapies and earlier gene-therapy programs. Commercial Respiratory Portfolio BRINSUPRI, or brensocatib, is a DPP1 inhibitor for non-cystic-fibrosis bronchiectasis....
On which exchange is INSM stock listed?
Insmed (INSM) is associated with NASDAQ, United States, Biopharma.
What is PALM-ILD?
Completion of enrollment in the Phase 3 PALM-ILD study in the first half of 2028.
Which conditions is Insmed targeting with PALM-ILD?
Insmed is associated with rare disease, respiratory disease based on its company overview and current catalyst commentary.
How does Insmed describe recent progress with PALM-ILD?
Completion of enrollment in the Phase 3 PALM-ILD study in the first half of 2028.
What is Serious?
Serious and Rare Diseases Insmed develops and commercializes therapies for serious pulmonary and rare diseases.